Effects of orthoptic therapy in children with intermittent exotropia after surgery: study protocol for a randomized controlled trial.
Intermittent exotropia
Orthoptic therapy
Randomized controlled trial
Study protocol
Suboptimal surgical outcome
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
11 Apr 2022
11 Apr 2022
Historique:
received:
03
09
2021
accepted:
28
03
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
14
4
2022
Statut:
epublish
Résumé
Intermittent exotropia (IXT) is the most common type of exotropia in China. Surgery is usually required to align the eye deviation to maintain or obtain better binocular visual function. However, there is a high rate of exodrift or recurrence in surgically treated patients. Orthoptic therapy is sometimes recommended for IXT patients after surgery. However, there is a lack of high-quality randomized controlled trials to prove that orthoptic therapy could be an effective supplement to surgical treatment for IXT patients. The main purpose of this study is to test the clinical effectiveness of orthoptic therapy in long-term stabilization of postoperative IXT patient. This report describes the design and methodology of the Intermittent Exotropia Postoperative Treatment Clinical Trial, which is the first large-sample, blank-controlled, randomized clinical trial. A total of 136 IXT patients (aged 7 to 17 years) will be enrolled and assigned to the orthoptic therapy group or blank control group according to a simple randomization scheme. Patients in the orthoptic therapy group will receive at least 2 months of orthoptic therapy, such as anti-suppression, vergence, and accommodation training. Patients in the blank control group will receive only refractive correction. All enrolled patients will need regular follow-up observation until 24 months after surgery. The primary outcome will be the proportion of participants meeting suboptimal surgical outcomes in this 24-month follow-up, which is defined as (1) exodeviation of 10 prism diopters (PD) at distance or near using the simultaneous prism and cover test (SPCT) or (2) loss of 2 or more octaves of stereoacuity from baseline, at any masked follow-up visit examination. The secondary outcomes will be the exodeviation at distance and near using the simultaneous prism and alternate cover test (PACT), magnitude of fusional convergence, stereoacuity, and accommodation. Measurements will be taken at baseline and at the 6-, 12-, 18-, and 24-month follow-ups. To the best of our knowledge, this will be the first prospective, randomized controlled study of orthoptic training in IXT patients after surgery. The aim of this work is to confirm the efficacy of orthoptic therapy in reducing the proportion of recurrence among IXT patients after surgery and improving binocular vision function. Chinese Clinical Trial Registry ChiCTR1900026891 . Registered on 25 October 2019.
Sections du résumé
BACKGROUND
BACKGROUND
Intermittent exotropia (IXT) is the most common type of exotropia in China. Surgery is usually required to align the eye deviation to maintain or obtain better binocular visual function. However, there is a high rate of exodrift or recurrence in surgically treated patients. Orthoptic therapy is sometimes recommended for IXT patients after surgery. However, there is a lack of high-quality randomized controlled trials to prove that orthoptic therapy could be an effective supplement to surgical treatment for IXT patients. The main purpose of this study is to test the clinical effectiveness of orthoptic therapy in long-term stabilization of postoperative IXT patient. This report describes the design and methodology of the Intermittent Exotropia Postoperative Treatment Clinical Trial, which is the first large-sample, blank-controlled, randomized clinical trial.
METHODS
METHODS
A total of 136 IXT patients (aged 7 to 17 years) will be enrolled and assigned to the orthoptic therapy group or blank control group according to a simple randomization scheme. Patients in the orthoptic therapy group will receive at least 2 months of orthoptic therapy, such as anti-suppression, vergence, and accommodation training. Patients in the blank control group will receive only refractive correction. All enrolled patients will need regular follow-up observation until 24 months after surgery. The primary outcome will be the proportion of participants meeting suboptimal surgical outcomes in this 24-month follow-up, which is defined as (1) exodeviation of 10 prism diopters (PD) at distance or near using the simultaneous prism and cover test (SPCT) or (2) loss of 2 or more octaves of stereoacuity from baseline, at any masked follow-up visit examination. The secondary outcomes will be the exodeviation at distance and near using the simultaneous prism and alternate cover test (PACT), magnitude of fusional convergence, stereoacuity, and accommodation. Measurements will be taken at baseline and at the 6-, 12-, 18-, and 24-month follow-ups.
DISCUSSION
CONCLUSIONS
To the best of our knowledge, this will be the first prospective, randomized controlled study of orthoptic training in IXT patients after surgery. The aim of this work is to confirm the efficacy of orthoptic therapy in reducing the proportion of recurrence among IXT patients after surgery and improving binocular vision function.
TRIAL REGISTRATION
BACKGROUND
Chinese Clinical Trial Registry ChiCTR1900026891 . Registered on 25 October 2019.
Identifiants
pubmed: 35410367
doi: 10.1186/s13063-022-06246-4
pii: 10.1186/s13063-022-06246-4
pmc: PMC8996411
doi:
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
289Subventions
Organisme : General Scientific Research Projects of Zhejiang Provincial Education Department
ID : Y201942103
Organisme : Natural Science Foundation of Zhejiang Province
ID : LY19H120004
Informations de copyright
© 2022. The Author(s).
Références
J Binocul Vis Ocul Motil. 2021 Oct-Dec;71(4):167-174
pubmed: 34449280
Br J Ophthalmol. 2013 Jul;97(7):870-3
pubmed: 23645821
Front Neurosci. 2021 Jul 05;15:685376
pubmed: 34290584
Korean J Ophthalmol. 2016 Feb;30(1):60-5
pubmed: 26865805
Ophthalmology. 2005 Jan;112(1):104-8
pubmed: 15629828
Eye (Lond). 2020 Feb;34(2):400-407
pubmed: 31406354
Eye (Lond). 2015 Feb;29(2):171-6
pubmed: 25397782
Indian J Ophthalmol. 1992 Jul-Sep;40(3):83-5
pubmed: 1302231
Strabismus. 2009 Jan-Mar;17(1):37-40
pubmed: 19301192
J Ophthalmol. 2016;2016:1489537
pubmed: 27022476
Am J Ophthalmol. 2007 Sep;144(3):465-7
pubmed: 17765436
Am Orthopt J. 1974;24:69-72
pubmed: 4830088
Eye (Lond). 2014 Jul;28(7):819-24
pubmed: 24788017
Arch Ophthalmol. 2008 Oct;126(10):1336-49
pubmed: 18852411
BMJ Open Ophthalmol. 2019 Mar 8;4(1):e000243
pubmed: 30997406
Strabismus. 2006 Sep;14(3):147-50
pubmed: 16950743
Sci Rep. 2019 Jun 6;9(1):8321
pubmed: 31171816
J AAPOS. 2019 Apr;23(2):79.e1-79.e7
pubmed: 30851413
Ophthalmic Epidemiol. 2008 Jan-Feb;15(1):24-36
pubmed: 18300086
Clin Exp Ophthalmol. 2006 Apr;34(3):245-51
pubmed: 16671905
BMJ. 2013 Jan 08;346:e7586
pubmed: 23303884
Medicine (Baltimore). 2016 Feb;95(5):e2590
pubmed: 26844467
Ophthalmology. 2019 Feb;126(2):305-317
pubmed: 30189281
Optom Vis Sci. 1992 May;69(5):386-404
pubmed: 1594200
Br J Ophthalmol. 2016 Apr;100(4):515-9
pubmed: 26261229
Ophthalmology. 2010 Jan;117(1):163-168.e1
pubmed: 19896195
J AAPOS. 2011 Apr;15(2):135-9
pubmed: 21419677
J AAPOS. 2010 Aug;14(4):298-304
pubmed: 20736121
Am J Ophthalmol. 2006 Apr;141(4):683-8
pubmed: 16564803